LBA: Probably the Best in Class for Treatment of Plaque Psoriasis

At this year’s EADV Congress, Dr. Blauvelt, Oregon, USA, presented a Late Breaking Abstract with promising results for a potent and highly selective allosteric TYK2 inhibitor for the treatment of plaque psoriasis. The results show a clinically effective and generally safe oral therapy for treating patients with moderate-to-severe plaque psoriasis.